• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    NeuroSense Therapeutics Ltd. - Ordinary Shares (NQ: NRSN )

    1.120 +0.100 (+9.80%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Jun 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 509,956
    Open 1.020
    Bid (Size) 1.120 (1)
    Ask (Size) 1.140 (4)
    Prev. Close 1.020
    Today's Range 0.9589 - 1.140
    52wk Range 0.4000 - 2.330
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024
    NRSN stock results show that NeuroSense Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023
    NRSN stock results show that NeuroSense Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace

    Performance

    YTD
    +40.00%
    +40.00%
    1 Month
    +3.70%
    +3.70%
    3 Month
    -38.80%
    -38.80%
    6 Month
    +40.00%
    +40.00%
    1 Year
    -24.83%
    -24.83%

    More News

    Read More
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
    Via Benzinga
    Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    US Stocks Higher; Private Payrolls Rise By 103,000 In November
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why SentinelOne Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC
    Via ACCESSWIRE
    Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeC
    Via Benzinga
    Stocks That Hit 52-Week Lows On Friday
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
    Via Benzinga
    Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Dow Drops 50 Points; Netflix Sales Top Estimates
    Via Benzinga
    Why Netflix Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Dow Drops 150 Points; Crude Oil Up 1%
    Via Benzinga
    Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Nasdaq Down Over 100 Points; Procter & Gamble Posts In-Line Earnings
    Via Benzinga
    NeuroSense Therapeutics (NASDAQ: NRSN) Shares Positive Final Results From Alzheimer’s Disease Biomarker Study
    Via Spotlight Growth
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.